Stem-cell exhaustion

Your body keeps a reserve of repair cells, the stem cells, that renew worn-out tissue throughout life. With age that reserve shrinks and works less well, so healing slows, muscle rebuilds poorly, and the immune and blood-forming systems falter. Most of what we know about slowing it comes from mice, and the injections and reprogramming therapies that get the headlines are unproven in people.

Lift weights: resistance training is the one lever shown to increase muscle stem cells in older adults. Sleep well and don't overeat, mainly for their broader, well-proven benefits. Stay away from stem-cell clinics, which have a documented harm record, and "young plasma" infusions, which the US regulator warns carry real risks.

Where upstream damage turns into visible decline

Stem-cell exhaustion is one of the hallmarks of aging, in both the original list of nine (2013) and the expanded twelve (2023). It is an integrative hallmark: less a root cause than the point where damage from the upstream hallmarks finally overwhelms the body's capacity to repair itself.[1][2]

Adult stem cells are the dedicated repair engines of each tissue: blood-forming cells in the bone marrow, satellite cells in muscle, neural stem cells in the brain, and the versatile mesenchymal stem cells that support many tissues. Most of the time they sit dormant in a protected resting state called quiescence; when tissue is damaged they wake, divide and rebuild.[3] With age both their numbers and their function decline, and the consequences are the syndromes that define frailty: muscle loss (sarcopenia), a weakened immune system, slow recovery from illness or injury, and failing tissue maintenance across the body.[4]

Why the reserve runs down

Stem cells wear out for two kinds of reason: damage inside the cells, and decay of the neighbourhood they live in.

Inside the cell. Decades of DNA damage, telomere shortening and epigenetic erosion corrupt the cell's instructions and blur its identity, so it loses control over when to rest and when to divide.[5] That balance is governed by the same growth- and energy-sensing machinery that runs the rest of metabolism; when nutrient sensing is deregulated, stem cells are pushed out of their resting state.[6] Failing mitochondria add to the damage.

Quiescence is the asset. The resting state is what protects the pool over a lifetime. When researchers force stem cells to divide continuously, they proliferate in a brief burst and then fail to sustain repair, exhausting the pool.[7] Aging erodes quiescence. In geriatric mice, muscle stem cells stop returning to reversible rest and slide into an irreversible pre-senescent state, driven by a cell-cycle brake (the p16 gene); silencing it restored their repair capacity, and the same gene is switched on in satellite cells from very old people.[8] When the cell's self-cleaning autophagy fails in aged satellite cells, they tip from rest into senescence, shown in mice and in human geriatric cells.[9]

The neighbourhood. A stem cell is only as healthy as its niche, the local structure of supporting cells, signals and scaffolding that tells it when to rest and when to act.[10] With age the niche degrades, and one large culprit is the build-up of senescent cells: damaged cells that stop dividing but linger, pouring out inflammatory signals. Inside a niche, those signals impair the stem cell's ability to self-renew and can tip healthy neighbours into senescence too.[11] This is the link to chronic inflammation: the inflamed tissue of older bodies is hostile to repair.

Muscle: the loss you can count

In muscle the decline is measurable in people, and specific. Older men carry roughly half as many satellite cells per fast-twitch fibre as young men, while slow-twitch fibres are largely spared. That was first seen in a small study of 16 men and then confirmed in 165 people, where fast-twitch satellite-cell numbers fell steadily with age across adulthood up to 86.[12][13]

These fast-twitch satellite cells also sit farther from their blood supply: in older men about 27% farther from the nearest capillary than in young men.[14] That seems to matter. In small studies over 24 weeks of resistance training, the older men with few capillaries around their fast-twitch fibres gained neither satellite cells nor muscle-fibre size, while those with better supply gained both.[15]

Blood: the one you can measure

Most of stem-cell exhaustion is invisible in a living person. The exception is the blood. With age, the bone marrow shifts toward making more inflammatory white cells and fewer lymphocytes,[16] and the large, diverse pool of blood-forming stem cells narrows: after about 75, in the few people sequenced in detail, 30 to 60% of all blood came from just 12 to 18 expanded clones.[17]

When an expanding clone carries a mutation in a growth-driver gene, the condition is called clonal hematopoiesis of indeterminate potential (CHIP): a mutant clone in someone with normal blood counts and no cancer. Standard sequencing finds it in about one in ten people over 65, rising to nearly one in five in their 90s.[18][19]

Carriers' absolute risk of a later blood cancer stays small, about 0.5% to 1% a year, although the first two large studies put it at 11 to 13 times that of non-carriers.[20][21] Pooled across 88 studies, carriers have about four times the blood-cancer risk of non-carriers, with about a third higher risk of death from any cause and about 75% higher risk of coronary heart disease. Risk depends on the gene and the clone's size; clones with only the most common mutation (DNMT3A) showed no clear extra risk of myeloid blood cancer or of death.[22] The heart link apparently runs through mutant immune cells stoking arterial inflammation.[23] The American Heart Association also links CHIP to heart failure, atrial fibrillation and blood clots.[24] One observational link cuts the other way: several studies tie CHIP to a lower risk of Alzheimer's dementia, though the largest found no Alzheimer's link and a modestly higher risk of brain disease linked to blood-vessel damage.[25][26]

Measurable does not yet mean actionable. No treatment aimed at CHIP has been shown to prevent heart disease, and testing healthy people is not part of routine care. Smoking, obesity and chronic inflammation help these clones expand, so the practical response is the usual one: don't smoke and keep cardiovascular risk factors in check.[27]

The brain: a genuine controversy

The tidy story, that the brain's stem-cell pool dwindles and takes memory with it, is much shakier in humans than in mice. Post-mortem studies from 2018–2019 disagreed sharply about whether adults form new neurons in the memory centre (the hippocampus) at all.[28][29] Newer studies that read the genetic activity of single brain cells now find dividing neural stem cells and young neurons in adult and older brains.[30][31] Some new-neuron formation probably persists into old age; how much, and whether it matters for memory, is still unknown.

Exhaustion is partly reversible, at least in mice

For a long time the decline looked like a one-way street. The more hopeful picture is that a meaningful share of it reflects a suppressed rather than destroyed cell. In transplant experiments, an aged stem cell placed in a young environment, or an old niche restored to better working order, can recover much of its lost function, so the niche's signals are doing a lot of the aging.[32] That shifts the goal from "replace the worn-out cells" to "fix the conditions holding them back", the basis for most rejuvenation research now moving toward the clinic.[33] In the blood, a second route has emerged: in aged mice, using antibodies to remove the inflammation-prone subset of blood-forming stem cells restored a younger-looking immune system and better responses to viral infection. It is untested in people.[34]

Much of this thinking traces to parabiosis, surgically joining the circulations of an old and a young mouse, which restored the repair capacity of aged muscle and liver stem cells.[35] The hunt for youthful blood factors that followed produced a cautionary tale: a protein called GDF11, reported to rejuvenate mouse muscle, could not be reproduced by an independent team.[36] Later mouse work suggested much of the benefit comes from diluting pro-aging factors in old blood instead.[37] In people, the first sham-controlled trial of plasma exchange found lower blood-based biological-age estimates midway, a difference that had disappeared by the end, with no health outcomes measured and several authors working for a plasma-exchange company.[38]

What actually helps

The levers that help are the familiar ones, and they fit the biology: exercise, sleep and diet act on the niches and the nutrient-sensing pathways that govern stem cells. Only exercise has direct stem-cell evidence in people.

Exercise, mainly for muscle stem cells. Resistance training is the most direct way to wake muscle satellite cells. In 51 older adults, 12 weeks of supervised strength training raised satellite-cell numbers in exactly the fast-twitch fibres that age depletes, and a pooled analysis of 19 studies points the same way, though it mixed very different measurements.[39][40] Blood supply seems to matter too: in one small study of 14 older men without a comparison group, mostly resistance training plus a weekly interval session sharpened the satellite-cell response most in the men who gained the most capillaries.[41] Whether endurance training does the same for older muscle stem cells is untested; the evidence so far is from young mice.[42]

For the brain, a randomised trial in 120 older adults found that a year of aerobic exercise enlarged part of the hippocampus by about 2%, with bigger gains going with better spatial memory and higher levels of brain-derived neurotrophic factor (BDNF), a growth factor that supports new neurons in animals. Whether this works through stem cells in people is unproven.[43] For the blood, people who get more moderate-to-vigorous activity are somewhat less likely to carry certain mutant clones, an observational link that cannot show cause and effect.[44] The practical side is on resistance training, zone 2, VO₂ max and bone density.

Sleep, so far in mice. In mice, healthy sleep keeps a brain signal (hypocretin) acting on the bone marrow that restrains the overproduction of inflammatory white cells; repeatedly broken sleep made blood stem cells divide more, raised inflammatory monocytes and enlarged artery plaques.[45] In people, cutting sleep short altered gene regulation in blood stem cells.[46] Whether poor sleep drives clonal hematopoiesis in people is unknown. Stem cells also follow a daily clock, which in old mice keeps ticking but shifts toward coping with stress.[47] No study has shown that a regular sleep schedule protects human stem cells, but keeping one aligned to your circadian rhythm is a low-cost habit that fits the biology.

Diet and fasting, mostly in animals, with a caveat. In animals, caloric restriction preserves stem cells partly by increasing their protective quiescence and improving the niche.[48] In the mouse gut, eating less lowers growth signalling (mTORC1, the growth-driving arm of the mTOR pathway) in the support cells around intestinal stem cells, boosting their function, and rapamycin mimics the effect.[49] Intermittent and periodic fasting are thought to protect stem cells by lowering inflammation and inducing autophagy.[50]

The caveat is in the refeeding. In mice, eating again after a 24-hour fast triggers a burst of gut stem-cell division. When a cancer-starting gene was knocked out during that refeeding window, more tumours formed than in fasted or normally fed mice.[51] This is mouse work and not a reason for healthy people to avoid fasting, and the study did not test what to eat when breaking a fast. A review of cell and animal work also warns that very prolonged calorie restriction can push autophagy into a harmful excess, which favours moderate regimens over extreme ones.[52]

The experimental frontier: nothing here is ready

Stem-cell transplants. The best trial so far infused donor bone-marrow stem cells into 148 frail older adults. At the main six-month check no dose clearly beat placebo; by nine months the highest dose, given to only 16 people, added about 63 metres to a six-minute walk. Gait speed, grip strength and self-reported function did not improve, and the trial was run by the company that makes the product.[53] Intravenous cell delivery carries its own risks. Details are on stem-cell therapy.

Partial reprogramming. Briefly switching on some of the "Yamanaka factors" can roll back a cell's epigenetic age while keeping its identity. In prematurely aged mice, short pulses eased signs of aging, and a version of the approach restored vision in aged and glaucoma-damaged mouse eyes.[54][55] The safety caveat is stark: keeping all four factors switched on continuously killed mice within days, and earlier studies found it caused teratomas (stem-cell tumours).[56] That is why the first human trial is confined to the eye; its developer announced the first participant dosed in June 2026, with no results yet.[57] More under partial reprogramming and epigenetic alterations.

Rejuvenating immune cells. Researchers are coaxing engineered cancer-fighting T-cells toward a long-lived, stem-cell-like memory state, though the signalling molecules involved can be dangerous at high doses.[58]

Drugs. Rapamycin restored the self-renewal of aged mouse blood stem cells.[59] At transplant doses, drugs that block mTOR suppress blood counts and raise infection risk. Low-dose trials in older adults were tolerable but gave mixed results,[60][61] and none measured stem cells. Metformin improves the "stemness" of human stem cells in the lab,[62] but in a trial of 94 healthy adults aged 65 and over it blunted the muscle gained from resistance training. It did not change the rise in muscle stem cells, but blunting the muscle gain matters, since training is the best lever here.[63]

NAD⁺ precursors show the mouse-to-human gap most cleanly. Restoring NAD⁺, a coenzyme that falls with age, rescued muscle, neural and pigment stem-cell function and modestly extended lifespan in aged mice.[64] But in 32 adults aged 55 to 80, nicotinamide riboside combined with pterostilbene did not improve muscle stem-cell recruitment or recovery after a muscle injury, and muscle NAD⁺ did not even rise.[65]

Supplements aimed at the niche (the senolytics fisetin and quercetin, spermidine, urolithin A) have a mouse rationale, strongest for the senolytics: giving very old mice dasatinib (a prescription cancer drug) plus quercetin to clear senescent cells improved physical function and lengthened remaining lifespan by about a third.[66] The human trials have mostly been disappointing. Dasatinib plus quercetin did no better than no treatment on the main bone marker in 60 postmenopausal women; a year of spermidine did not improve memory in 100 older adults with self-reported memory worries; and the urolithin A trials for muscle are small and inconclusive.[67][68][69] None measured tissue stem cells. At most these are plausible add-ons. More under cellular senescence and mitochondrial dysfunction.

The harm the hype has already done

In 2021, more than 2,700 clinics in the United States were selling stem-cell treatments the US Food and Drug Administration (FDA) has never approved.[70] A 2021 tally by the Pew Charitable Trusts found reports of at least 360 people harmed worldwide between 2004 and 2020, including 20 deaths, 9 cases of partial or complete blindness and over 100 hospitalizations, probably an undercount.[71] In one widely reported case, three women were blinded after a clinic injected fat-derived "stem cells" into their eyes for macular degeneration.[72]

"Young plasma" infusions are a related trap: in 2019 the FDA warned that they have no proven benefit against aging or memory loss and carry infection, allergy, lung and heart risks.[73]

Almost every mechanism on this page, from the signalling pathways to young-blood factors, reprogramming, NAD⁺ and senolytics, rests on mouse data. The solid human evidence is mostly observational (the clonal hematopoiesis cohorts, the satellite-cell counts) or comes from small trials. "Build muscle, sleep well, don't overeat" remains a better stem-cell strategy than anything currently sold as one.

Further reading

  • Brunet A, Goodell MA, Rando TA. Ageing and rejuvenation of tissue stem cells and their niches. Nat Rev Mol Cell Biol 2023.[74]
  • Rezazadeh S, Ellison-Hughes GM. Editorial: Stem cell exhaustion in aging. Front Aging 2024.[75]
  • Boyette LB, Tuan RS. Adult stem cells and diseases of aging. J Clin Med 2014.[76]
  • Garay RP. Recent clinical trials with stem cells to slow or reverse normal aging processes. Front Aging 2023.[77]
  • Saliev T, Singh PB. From bench to bedside: translating cellular rejuvenation therapies into clinical applications. Cells 2024.[78]
  • Heidari D, et al. The resistance training effects on skeletal muscle stem cells in older adult: a systematic review and meta-analysis. Cell J 2023 — pools 19 studies with very different measurement methods.[79]
  • Snijders T, et al. Prolonged exercise training improves the acute type II muscle fibre satellite cell response in healthy older men. J Physiol 2019 — n=14, no control group.[80]
  • McAlpine CS, et al. Sleep modulates haematopoiesis and protects against atherosclerosis. Nature 2019 — mouse study.[81]
  • Maharajan N, et al. Caloric restriction maintains stem cells through niche and regulates stem cell aging. J Mol Med (Berl) 2020 — review of mostly animal work.[82]
  • Imada S, et al. Short-term post-fast refeeding enhances intestinal stemness via polyamines. Nature 2024 — mouse study; the refeeding-and-tumour finding behind the fasting caveat.[83]
  • Mitchell E, et al. Clonal dynamics of haematopoiesis across the human lifespan. Nature 2022 — deep sequencing of a small number of people.[84]
  • Jaiswal S, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 2017.[85]
  • Ruiz JG, et al. Randomized phase 2b dose-escalation trial of stem cell therapy with laromestrocel for aging frailty. Cell Stem Cell 2026 — n=148; no dose clearly beat placebo at the six-month primary check; run by the product's maker.[86]

— § —